share_log

Cantor Fitzgerald Initiates Coverage On Fulcrum Therapeutics With Overweight Rating, Announces Price Target of $23

Cantor Fitzgerald Initiates Coverage On Fulcrum Therapeutics With Overweight Rating, Announces Price Target of $23

坎託·菲茨傑拉德以增持評級開始對Fulcrum Therapeutics進行報道,宣佈目標股價爲23美元
Benzinga ·  05/20 19:46

Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Fulcrum Therapeutics (NASDAQ:FULC) with a Overweight rating and announces Price Target of $23.

坎託·菲茨傑拉德分析師克里斯汀·克魯斯卡以增持評級開始對Fulcrum Therapeutics(納斯達克股票代碼:FULC)進行報道,並宣佈目標股價爲23美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論